The global clinical trials activity saw an increase of 16.6% in Q4 2020, when compared with the rolling average of the last four quarters (Q4 2019 to Q3 2020), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 55.6% share in Q4 2020, marking a increase of 8.2% in the total share when compared with the four-quarter average.
Non-industry sponsored trials accounted for a 44.4% share of all the clinical trials globally in Q4 2020, marking an decrease of 8.2% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q4 2020
Oncology was the leading therapy area for industry sponsored clinical trials in Q4 2020, accounting for a 30.8% share of all trials.
This was followed by the following therapy areas: Infectious Disease with an 18.5% share, Central Nervous System with a 12.1% share, Metabolic Disorders with a 7.0% share and Respiratory with a 6.4% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 26.6% share, followed by Infectious Disease with an 18.9% share, Central Nervous System with a 13.3% share, Respiratory with an 8.9% share, and Metabolic Disorders with a 7.8% share.
Industry sponsored trials activity: 4-Quarter Avg. vs Q4 2020 | |||
---|---|---|---|
Therapy Area | 4-Quarter Avg. | Q4 2020 | Activity |
Oncology | 26.6% | 30.8% | ![]() |
Infectious Disease | 18.9% | 18.5% | ![]() |
Central Nervous System | 13.3% | 12.1% | ![]() |
Metabolic Disorders | 7.8% | 7.0% | ![]() |
Respiratory | 8.9% | 6.4% | ![]() |
Immunology | 5.0% | 5.6% | ![]() |
Cardiovascular | 7.5% | 5.3% | ![]() |
Gastrointestinal | 6.9% | 5.1% | ![]() |
Dermatology | 4.4% | 3.9% | ![]() |
Musculoskeletal Disorders | 3.6% | 3.8% | ![]() |
Hematological Disorders | 2.8% | 3.2% | ![]() |
Ophthalmology | 2.7% | 3.2% | ![]() |
Genito Urinary System And Sex Hormones | 2.7% | 2.3% | ![]() |
Genetic Disorders | 1.6% | 2.2% | ![]() |
Women’s Health | 2.0% | 1.5% | ![]() |
Ear Nose Throat Disorders | 1.6% | 0.7% | ![]() |
Male Health | 0.9% | 0.6% | ![]() |
Hormonal Disorders | 0.6% | 0.4% | ![]() |
Nutritional Disorders | 0.4% | 0.4% | ![]() |
Mouth and Dental Disorders | 0.6% | 0.3% | ![]() |
Non Malignant Disorders | 0.2% | 0.1% | ![]() |
Oncology was the leading therapy area for non-industry sponsored clinical trials in Q4 2020, accounting for a 26.4% share of all trials.
This was followed by the following therapy areas: Central Nervous System with a 22.7% share, Infectious Disease with a 16.6% share, Cardiovascular with a 9.6% share, and Gastrointestinal with a 6.4% share.
In the last four quarters, Oncology held a lead over others for non-industry sponsored clinical trials with an average share of 21.4%, followed by Infectious Disease with a 21.3% share, Central Nervous System with a 20.9% share, Respiratory with an 8.4% share, and Cardiovascular with an 8.1% share.
Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q4 2020 | |||
---|---|---|---|
Therapy Area | 4-Quarter Avg. | Q4 2020 | Activity |
Oncology | 21.4% | 26.4% | ![]() |
Central Nervous System | 20.9% | 22.7% | ![]() |
Infectious Disease | 21.3% | 16.6% | ![]() |
Cardiovascular | 8.1% | 9.6% | ![]() |
Gastrointestinal | 6.1% | 6.4% | ![]() |
Metabolic Disorders | 4.9% | 5.8% | ![]() |
Respiratory | 8.4% | 5.6% | ![]() |
Musculoskeletal Disorders | 4.5% | 4.3% | ![]() |
Women’s Health | 4.7% | 4.0% | ![]() |
Hematological Disorders | 2.8% | 2.9% | ![]() |
Immunology | 3.0% | 2.9% | ![]() |
Dermatology | 2.9% | 2.8% | ![]() |
Genito Urinary System And Sex Hormones | 2.9% | 2.6% | ![]() |
Mouth and Dental Disorders | 2.1% | 1.6% | ![]() |
Ophthalmology | 1.6% | 1.6% | ![]() |
Nutritional Disorders | 0.6% | 0.9% | ![]() |
Hormonal Disorders | 0.6% | 0.8% | ![]() |
Ear Nose Throat Disorders | 1.1% | 0.6% | ![]() |
Genetic Disorders | 0.6% | 0.6% | ![]() |
Male Health | 0.6% | 0.5% | ![]() |
Non Malignant Disorders | 0.3% | 0.4% | ![]() |
Top regions in industry and non-industry sponsored clinical trials activity in Q4 2020
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q4 2020 with a 45.5% share, compared to 53.1% in the last four quarters.
North America stood at second place with a 40.0% share in Q4 2020, over 31.8% in the last four quarters, followed by Europe with a 30.0% share in Q4 2020, as against 28.2% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 82.3% share in industry sponsored clinical trials in Q4 2020 when compared with 84.5% of average recorded in the last four quarters. Multinational trials accounted for a 17.7% share in Q4 2020, as against the four-quarter average of 15.6%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q4 2020 with a 47.0% share, over 47.4% in the last four quarters.
North America held the second position with a 25.4% share in Q4 2020, over 17.0% in the last four quarters, followed by Europe with a 15.0% share in Q4 2020, as against 15.3% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.6% share for non-industry sponsored clinical trials in Q4 2020, compared to 98.7% in the last four quarters. Multinational trials accounted for a 1.4% share in Q4 2020, as against 1.3% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q4 2020
Phase II trials outnumbered all other studies with a 39.1% share for industry sponsored trials in Q4 2020, compared to 34.9% average in the last four quarters.
The share of Phase I trials stood at 31.6% in Q4 2020, as against the four-quarter average of 36.3%. Phase III trials held a 19.2% share in Q4 2020, registering an increase of 2.3% over the last four quarters average, followed by Phase IV trials with a 10.1% share in Q4 2020, as against the four-quarter average of 11.8%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 47.4% share for non-industry sponsored clinical trials in Q4 2020, compared to 42.5% in the last four quarters.
Phase IV trials stood at second place with a 19.3% share in Q4 2020, compared to 19.6% in the last four quarters. Phase III trials held a 16.8% share in Q4 2020, as against 21.4% in the last four quarters, followed by Phase I trials with a 16.5% share in Q4 2020 over 16.4% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.